Business Services Industry

Despite Elite Rating, Huge Sales, Expanded Pfizer Still Faces Challenges.

Knight Ridder/Tribune Business News, May, 2003

By Matthew Lubanko, The Hartford Courant, Conn. Knight Ridder/Tribune Business News

May 4--Despite spending tens of billions of dollars to buy two companies over the last three years, Pfizer Inc. still retains an elite Triple-A credit rating.

That Triple-A rating places Pfizer in a select club with just seven other U.S. companies. The drug-maker employs 6,000 in the Groton-New London area of Connecticut.

But that Triple-A rating only assures bondholders that Pfizer can make good on its debts. It does not suggest that investors should run out and buy Pfizer stock -- and expect to ride with the mega-drug-maker for 10 more years of unmatched prosperity. The new Pfizer is far different from the one that delivered annualized returns...

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works. HighBeam Research
 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement